Metastatic

HER2 +

3rd line or later

- BRS0131
  Phase I/II IV
  Zolatatin
  (eFT226) in
  Selected
  Advanced Solid
  Tumor
  Malignancies
  PI: Caswell-Jin
  eFFECTOR
  Therapeutics, Inc.
  Priority 1

- BRS0115
  Expanded
  Access
  Pertuzumab &
  Trastuzumab
  Fixed-Dose
  Combo in
  HER2+ Breast
  Cancer During
  COVID-19 Pan
  PI: Riaz
  Genentech

- BRS0142
  Phase I/II Open Label
  Dose Escalation and
  Dose Expansion Study
  to Evaluate Safety,
  Tolerability, Dosimetry,
  and Preliminary
  Efficacy of HER2
  Directed Radioligand
  CAM-H2 in
  Advanced/Metastatic
  HER2-Positive Breast,
  Gastro, &
  Gastro-Esophageal
  Junction Cancer
  PI: Aparici
  Sponsor: Precirix NV

[Diagram of trial options and priorities]